

# 1           **Optimizing Research Data Acquisition with Smart Pill Bottles (SPBs), the** 2           **ORDAS Trial: A Feasibility and Implementation Study Protocol**

3  
4 Short Title: Using smart pill bottles to optimize data collection in clinical trials: a study protocol

5  
6 Nicolas Daccache<sup>1,2</sup> MD; Joe Zako<sup>1,2</sup> MD; Julien Burey MD<sup>1,2,3</sup>; Olivier Verdonck<sup>1,2</sup> MD, MSc; François  
7 Martin Carrier MD, MSc, FRCPC<sup>1,4</sup>; Louis Morisson MD, MSc, PhDc<sup>1,2</sup>; Pascal Laferrière-Langlois MD,  
8 MSc<sup>1,2</sup>

9 <sup>1</sup> Department of Anesthesiology and Pain Medicine, Maisonneuve-Rosemont Hospital, Centre intégré universitaire de santé et  
10 service sociaux de l'Est de L'Île de Montréal, Montréal, Québec, Canada

11 <sup>2</sup> Maisonneuve-Rosemont Hospital Research Center, Montréal, Québec, Canada

12 <sup>3</sup> Department of Anesthesiology and Critical Care Medicine, Tenon Hospital, APHP Sorbonne Université, Paris, France

13 <sup>4</sup> Département d'anesthésiologie, Université de Montréal

14  
15 Corresponding author : **Nicolas Daccache**, Department of Anesthesiology and Pain Medicine,  
16 Maisonneuve-Rosemont Hospital, Centre intégré universitaire de santé et service sociaux de l'Est de L'Île  
17 de Montréal. 5415 boulevard de l'Assomption, Montréal, Québec H1T 2M4, Canada  
18 Phone number: +1-514-557-1803 Email: [nicolas.daccache@mail.mcgill.ca](mailto:nicolas.daccache@mail.mcgill.ca)  
19 ORCID : 0009-0005-2025-802X

## 20 Authors:

21 Nicolas Daccache : [nicolas.daccache@mail.mcgill.ca](mailto:nicolas.daccache@mail.mcgill.ca) (0009-0005-2025-802X)

22 Joe Zako : [joe.zako@umontreal.ca](mailto:joe.zako@umontreal.ca)

23 Julien Burey : [julien.burey@umontreal.ca](mailto:julien.burey@umontreal.ca) (0000-0003-2792-9883)

24 Olivier Verdonck : [olivier.verdonck@umontreal.ca](mailto:olivier.verdonck@umontreal.ca) (0000-0003-4431-8785)

25 François Martin Carrier : [francois.martin.carrier@umontreal.ca](mailto:francois.martin.carrier@umontreal.ca)

26 Louis Morisson : [louis.morisson@umontreal.ca](mailto:louis.morisson@umontreal.ca) (0000-0003-4431-8785)

27  
28  
29 Funding: This study will be supported by funds from Dr Pascal Laferrière-Langlois at the LIAM  
30 (Laboratory of innovative anesthesia in Montreal) and the Department of Anesthesiology and Pain  
31 Medicine. Appmed inc. provided the smart pill bottles and funding for the trial.

## 32 Declaration of interests:

33 Dr PLL declares ownership interest in private companies unrelated to this work (Divocco Medical and  
34 Divocco AI). Other authors declare no competing interests.

35  
36  
37 Protocol version: 2, October 8th, 2024

38  
39 Ethics: This trial has been approved by the regional ethics committee (Comité d'Éthique de la Recherche -  
40 CIUSSS de l'Est de l'Île de Montréal).

41  
42 Data availability: Additional data including patient consent forms and questionnaires will be made available  
43 upon reasonable request to the corresponding author.

44  
45 Keywords: Smart pill bottles, major abdominal surgery, connected technology, opioid consumption

## 46 **Abstract**

47 Introduction: Clinical trials are fundamental to advancing all areas of medicine. Despite their  
48 importance, trials are often expensive and time-consuming due to the need for extensive human  
49 resources, with limitations in cohort sizes and potential biases from loss of follow-up. Smart pill  
50 bottles (SPBs) offer a promising innovation by automating data collection, which could reduce  
51 costs and improve the granularity and accuracy of data. This technology may provide a more  
52 efficient alternative to traditional methods, streamlining data acquisition in clinical research.

53 Objectives: This proof-of-concept study aims to assess the feasibility of using smart pill bottles  
54 (SPBs) to collect data on opioid consumption in a postoperative setting, comparing their cost-  
55 efficiency and data quality to traditional methods. We hypothesize that SPBs will be readily  
56 adopted by users and enable the collection of highly granular data with fewer missing data points,  
57 while reducing the costs associated with human resource-based data collection.

58 Material and Methods: This single-center, single-arm trial will enroll 69 patients aged 18 and  
59 above undergoing major abdominal surgery via laparotomy. Following recruitment, patients will  
60 complete web-based questionnaires assessing pain, comorbidities, and quality of life.  
61 Postoperatively, patients will receive an SPB, the Thess Therapy Smart System manufactured by  
62 Thess Corporate (France) and provided by AppMed Inc. (Canada) to monitor opioid consumption  
63 at home for up to 90 days. At the end of the study period, participants will use the web-based  
64 platform to complete the same questionnaires, an opioid compliance checklist and a product  
65 satisfaction survey. The primary outcome will be the percentage of patients who successfully use  
66 the SPB throughout the study period. Secondary outcomes will include the extent of automated  
67 data collection, data granularity, project costs, the incidence of persistent opioid consumption, and  
68 patient satisfaction with the SPB.

69 Trial registration: [clinicaltrials.gov](https://clinicaltrials.gov) (July 25th, 2024). Unique protocol ID: 2025-3801. NCT number:  
70 NCT06522698.

71

72

73

74

75

76

77

78

## 79 1. Background

80 Clinical trials are a fundamental component of clinical research, providing valuable evidence  
81 for assessing the efficacy and safety of medical interventions. In recent years, the number of  
82 published clinical trials has grown significantly, with estimates indicating that over 20,000  
83 trials are initiated annually by drug developers. (1). This surge reflects the increasing reliance  
84 on rigorous scientific methods to inform medical practice and policy. While studies on large  
85 samples of patients are highly beneficial, a notable drawback lies in their time-consuming  
86 nature and the associated costs they incur. Moreover, the size of cohorts may be limited by the  
87 human resources and funds available, and loss of follow-up is an intrinsic risk to clinical trials  
88 that may introduce bias (2, 3). Despite the high costs, these investments are justified by the  
89 critical role that clinical trials play in advancing medical knowledge and improving patient  
90 outcomes. However, it is evident that developing tools to optimize the methods used in trials  
91 with the aim of increasing cost-efficiency would be highly beneficial given the substantial  
92 financial investments involved. Improved cost-efficiency could facilitate recruitment of larger  
93 patient cohorts and enhance the quality and diversity of research outputs assessed, ultimately  
94 leading to more robust and comprehensive findings. So how can we push the modernization of  
95 clinical research further, and what novel technologies could be used to streamline and automate  
96 data collection to increase cost-efficiency of research?

97 Several studies involving harnessing new technology to approach data collection have  
98 suggested that a streamlined and automated method of collecting data through connected  
99 technology can help set up clinical trials more cost-effectively (4, 5, 6). Evaluating the use of  
100 a connected device as a research tool in clinical trials and comparing it with traditional data  
101 collection using human resources would provide valuable insights into its efficiency and  
102 effectiveness. Smart medication adherence monitoring devices are a novel technology that  
103 provides objective and granular medication utilization data along with engaging patients with  
104 their treatment (7). Particularly, the smart pill bottle (SPB) is a rapidly developing technology  
105 that allows for medication monitoring of solid doses with the use of electronic sensors that can  
106 collect data on medication usage in real time and offer direct communication between patients  
107 and healthcare professionals or trialists (8). SPBs have shown efficacy in monitoring  
108 compliance and possibly increasing medication adherence in the clinical setting and the  
109 technology has been suggested as a potential research tool that would allow automatic  
110 collection of granular and precise data on the time of medication intake, dose, and frequency.  
111 (9, 10,). However, to our knowledge, there hasn't been a trial comparing the efficacy of using  
112 SPBs for data collection in clinical trials versus the traditional method reliant on human  
113 resources in comparable contexts. Based on the properties of SPBs and available literature  
114 supporting the automatization and streamlining of data in clinical trials (4, 5, 6, 9, 10), we  
115 believe that the use of these devices may allow data collection of higher quality regarding  
116 granularity, number of losses of follow-up, completeness, missing data points along with a  
117 reduction of costs incurred by avoiding the use of human resources.

118 Earlier this year, the POCAS (Persistent opioid consumption after major abdominal surgery  
119 and its determinants) study was started at the University of Montreal. This prospective cohort  
120 study examined the prevalence of persistent opioid consumption (POC) three months post-  
121 surgery, its link to chronic postsurgical pain (CPSP), quality of life impacts, and risk factors.  
122 Researchers followed 668 patients, collecting opioid consumption data via telephone surveys  
123 and pharmacy reports, which required significant time and human resources. The POCAS trial  
124 is an example of a study in which the use of SPB could automate data acquisition, potentially  
125 reducing human cost while increasing the granularity of data (i.e. daily use vs monthly use).

126 This single group proof of concept study will mimic the POCAS trial methodology while  
127 incorporating SPB to explore its application in clinical research. More specifically, we aim to  
128 explore the level of adoption of SPBs in the context of postoperative research, describe the  
129 quality of data acquired, and describe the cost of data acquisition for a comparison with  
130 historical data.

## 131 2. Objectives and Hypotheses

132 Our primary objective is to evaluate the adoption of smart pill bottles (SPBs) in postoperative  
133 settings, to improve the process of data collection in the context of clinical trials.

134 Our secondary objectives will be to:

- 135 - Evaluate the quality of research data collected from patients regarding opioid consumption  
136 up to 90 days after major abdominal surgery with SPBs in the following metrics:  
137 automation of data collection, granularity of the data, number of missing data points.
- 138 - Evaluate the costs incurred for research data acquisition, using SPBs compared to standard  
139 practice using human resources, and compare these costs with historical cohorts.
- 140 - Estimate the prevalence of POC and CPSP 90 days after major abdominal surgery defined  
141 as the consumption of any quantity of opioids in the 7 days prior to the 90-day  
142 interrogation, describe its distribution in both opioid-naïve and chronic opioid consumers  
143 and across different types of abdominal surgery, and estimate its association with persistent  
144 pain and quality of life.
- 145 - Evaluate patient satisfaction with the use of SPBs.

146 Our exploratory objective is to explore how increased granularity of data collected in real time  
147 by the SPBs can enable deeper statistical analysis, in this specific case, build the trajectory of  
148 opioid consumption during the 90-day period to potentially identify patients at risk of  
149 developing chronic opioid consumption through predictive algorithms.

150

151

152 We hypothesized that:

- 153 - The implementation of SPBs as a data collection tool in clinical trials will be feasible, with  
154 patients expected to use the SPBs correctly at a rate of 80%, (11).
- 155 - The data generated from the SPB will be of high quality (increased granularity, lower  
156 missing data rate) as suggested by literature on similar products in clinical settings
- 157 - The costs involved in carrying out this project with the help of the SPBs will be lower than  
158 those incurred during the original POCAS study which collected data through human  
159 resources.
- 160 - The rate of POC will approximate 10%, as reported in the POCAS trial.
- 161 - Most patients will be satisfied with the use of the SPB, similarly to previously reported  
162 results (12).

### 163 **3. Design and Methods**

#### 164 a. Design

165 The project will be a one-arm single-site trial conducted at the CIUSSS-de-l'Est-de-l'Île-de-  
166 Montréal (Hôpital Maisonneuve-Rosemont).

#### 167 b. Population

168 The study population will consist of all consenting adult patients (age  $\geq 18$  years) undergoing  
169 major abdominal surgery via laparotomy (any open surgery involving the abdominal  
170 compartment or its wall, excluding appendectomies, inguinal hernia repairs, abdominal wall  
171 hernia repairs, and incisional hernia repairs). The population was chosen to resemble that of  
172 the POCAS study to ensure comparability.

173 Exclusion criteria include patients enrolled in the historical cohort (POCAS study) or currently  
174 participating in another study, patients undergoing additional surgery within 90 days post-  
175 hospital discharge, patient who will be oriented to a secondary care facility or rehabilitation  
176 centers and patients who do not understand French or English. We will also exclude patients  
177 with allergies or intolerance to hydromorphone, and for which hydromorphone is not the  
178 standard of care for postoperative pain management (see section below on Logistical  
179 Consideration).

#### 180 c. Outcomes

181 Our primary outcome will be the percentage of patients that will have appropriately adopted  
182 the SPB until the end of the 90-day period or until the absence of pain, defined as no  
183 hydromorphone intake for 72 hours. Non-adoption will be defined as the requirement to  
184 consume medication without the intended use of the SPB.

185 Our secondary outcomes will include:

- 186 - Automation of data collection, assessed by the number of human interventions required  
187 throughout the data collection process for each patient.
- 188 - Granularity of the data, assessed by the number of consumptions at each hour of every day.
- 189 - Total dose of opioid consumed (converted to daily oral morphine equivalent).
- 190 - Percentage of captured consumptions, assessed by the number of opioid capsules  
191 consumption properly tracked by the SPB, divided by the total number of capsules missing  
192 at the end of the protocol. In example, if the SPB tracked 18 capsules consumption, but 20  
193 pills are missing from the container when retrieved, the percentage will be 90%.
- 194 - Percentage of questionnaires properly filled without interventions from the research staff.
- 195 - Percentage of patients who respected the initial prescription of opioid made by the  
196 physician upon hospital discharge. In example, if a patient received a prescription of  
197 hydromorphone 2 mg q4h PRN, and a delay below 4h between two consumptions was  
198 registered by the SPB, the patient will be deemed not to have followed the initial  
199 prescription.
- 200 - The costs incurred per patient from carrying out the project (research staff salaries, cost of  
201 device acquisition and daily use).
- 202 - Persistent opioid consumption (POC) 90 days after surgery as reported by the SPBs. POC  
203 will be defined as consumption of any quantity of opioids in the 7 days prior to the 90-day  
204 interrogation. This definition will be accurate for both preoperative chronic and non-  
205 chronic opioid users.
- 206 - The presence of CPSP in the 7 days prior to the interrogation. CPSP will be defined as any  
207 pain at the surgical site for patients who had pain at that site before surgery (by 1 point on  
208 the general numerical pain scoring question of the BPI questionnaire) (14).
- 209 - The change in the reported quality of life at the same time point. QOL will be measured  
210 as a continuous variable on the SF-12 questionnaire (15). These surveys have been selected  
211 to allow accurate comparison with the POCAS cohort as these were the surveys used in the  
212 context of that study.
- 213 - Patient satisfaction with the use of the SPB reported through a custom questionnaire

#### 214 d. Data Collection and Measurements

215 Once consent is obtained, we will complete the baseline interview with 5 questionnaires listed  
216 below in a period of approximately 20 minutes, either in person or by phone depending on  
217 availability. During this interview, we will gather baseline patient characteristics, including  
218 demographic information (age, sex, ethnicity, BMI, geographic location, economic status),  
219 medical and surgical history, preoperative medications, and the occurrence and location of  
220 preoperative pain. Chronic preoperative opioid usage will be determined as the intake of  
221 opioids for over three months before surgery (16).

222 We will use a modified short Brief Pain Inventory (BPI) questionnaire, adjusting it to inquire  
223 about pain over the previous 7 days instead of 24 hours, and replacing the body map question  
224 with a query about the pain site to distinguish surgical site pain from other pain locations.  
225 Additional questions in the questionnaire will address the chronic nature of preoperative pain.  
226 For chronic opioid users, we will collect data on the reasons for opioid use (if not solely for  
227 pain) and the duration of use.

228 We will assess comorbidities using the Charlson Comorbidity Index (CCI) (17). Baseline data  
229 on anxiety symptoms, depressive symptoms, catastrophizing tendencies, and quality of life  
230 will be collected using the PHQ-4, PCS-4, and SF-12 questionnaires, respectively (15, 18, 19).  
231 No intraoperative data will be recorded.

232 Following their surgery, all patients will be provided a SPB (Thess Therapy Smart System  
233 device, distributed by AppMed Inc, Québec, Canada), which will be used by patients to  
234 consume opioids and simultaneously record the consumption. Data regarding the dosage  
235 frequency, including the exact time of each consumption, will be continuously collected by the  
236 devices. During the 90-day post-op period, we will record any new hospitalizations, morbidity,  
237 or mortality.

238 If a patient's medication consumption is not recorded by the SPB for 48 hours, they will  
239 automatically receive a notification inquiring about the reason for the cessation. More  
240 specifically, the patient will be asked whether the cessation is due to the absence of pain or  
241 another reason. If no answer is obtained within 24h, the research staff will directly contact the  
242 patient.

243 At the end of the 90-day post-op period, the patients will be prompted to use the proprietary  
244 web platform (Thess, France or p-Dose, AppMed Inc. Canada) to respond to end-of-trial  
245 surveys (PHQ-4, PCS-4, BPI, self-reported opioid consumption questionnaire, OCC checklist,  
246 SF-12 and patient satisfaction questionnaire). Once the SPB is retrieved, we will assess the  
247 number of capsules remaining in the container, and verify the integrity of the sticker,  
248 confirming that no medication was consumed outside of the normal dispensary mechanism.

#### 249 e. Patient recruitment and timeline

250 The research team will assess the elective surgical list of Maisonneuve-Rosemont Hospital's  
251 operating room to identify eligible patients at least one week before their scheduled surgery.

252 Potential patients will be contacted by the research team via phone at least 3 days before  
253 surgery to provide an explanation of the project. The communication form used during these  
254 calls will be approved by the Maisonneuve-Rosemont Hospital Ethics Committee. Once  
255 consent is obtained and the consent form is adequately filled either via the REDCap application  
256 or via web signature (20), a thorough review of the patients' medical charts will be conducted

257 to confirm that they meet the inclusion criteria and have no exclusion criteria. Once eligibility  
258 is confirmed and patients are enrolled, the research team will meet the candidates before the  
259 surgery to complete the initial assessment, and to address any questions the patient may have.  
260 A first presentation of the SPB and how it works will be made by the research staff, but patients  
261 will be informed that a second demonstration will be completed prior to post-surgery hospital  
262 discharge.

263 After the surgery, once the patient recovered and there is imminent hospital discharge, the  
264 research staff will meet with the patient for a second demonstration of the SPB and the  
265 logistical consideration (SPB medication refill, retrieval at the end of the trial, etc.)

266 The 90-day monitoring period will start at the end of the final surgical procedure conducted  
267 during the initial hospital stay. This duration was selected because it aligns with the commonly  
268 accepted cutoff for identifying chronic persistent surgical pain, and is widely acknowledged in  
269 current research on postoperative patient outcomes and provides an advantageous window for  
270 potential preventive or preemptive interventions (21, 22, 23). It is also the time frame used in  
271 the POCAS study, facilitating the comparison with this historical cohort.

272 Throughout the 90-day monitoring period and depending on the consumption habit, the patient  
273 will be prompted to answer questionnaires on pain management via an automated system (i.e.  
274 email). If no answer is obtained within 24-48h, the research staff will directly contact the user  
275 to ensure questionnaire completion.

276 At the end of the 90-day monitoring period, the patient will be prompted to answer the final  
277 questionnaires and to return the SPB if it is still in his possession. If the patient still consumes  
278 opioids and needs an additional prescription, a consultation with his medical team will be  
279 organized to ensure the transition from the SPB use to standard prescription- and pharmacy-  
280 based medication dispense. Once these steps are completed, the patient's research involvement  
281 will be completed. The timeline of events is illustrated in **Figure 1**.

282 **Figure 1** SPIRIT Schedule of Enrolment, Interventions and Assessments

283

284

285

286

287

288



289 We will recruit and collect data from patients at the CIUSSS-de-l'Est-de-l'Île-de-Montréal  
290 ((HMR) Hôpital Maisonneuve-Rosemont over a period of 12 months, starting in December  
291 2024. A realistic estimate would be a recruitment of 3 patients per week over 23 weeks, which  
292 would amount to 69 patients included over approximately 5 months. A less favorable estimate  
293 would be a recruitment period of 9 months, followed by the 3-month period of follow-up and  
294 data collection. The rate of recruitment will be impacted by the number of SPB available, as  
295 provided by the commercial distributor. This work rate would allow the data analysis and  
296 submission of our initial results to be carried out within a 14-month frame.

#### 297 f. Description of SPB and logistical consideration

298 The SPB functions through a pressure sensitive cap that dispenses encapsulated medication  
299 when triggered. The SPB will provide medication without any dose and time restrictions,  
300 mimicking any standard container provided by a pharmacy. The patient will be instructed to  
301 solely request medication via the SPB dispenser mechanism and not to open the medication  
302 container. A sticker will be placed on the medication container to capture any instance of  
303 sticker tearing, indicating that the patient opened it.

304 Patients will also be instructed to present themselves back to the hospital center in the case of  
305 losing or breaking a smart pill bottle. A phone support line will be available to the patients 24  
306 hours a day, 7 days per week for any problem with the hardware or software components.

307 Due to SPB current technological limitation, only encapsulated medication can be dispensed.  
308 Opioids are standardly not encapsulated, requiring us to manually encapsulate the medication  
309 use during this trial. The corollary of this limitation is that only the research pharmacy from  
310 Maisonneuve Rosemont hospital can provide the medication. Patients will initially be provided  
311 a dispenser with a maximum of 30 capsules and, and if needed, will have to contact the research  
312 staff and present themselves at the hospital to receive any refill.

313 Once patient has signaled no pain or medication requirement after being prompted by the  
314 research staff 48h following their last consumption, an additional period of 5 days without  
315 consumption will be given before retrieving the SPB. This additional period aims to account  
316 for any recurrence of pain and medication consumption, which would reinitiate the medication-  
317 free 48h required for completion of treatment. If no medication was requested for these 7  
318 consecutive days, the research staff will retrieve the SPB, either via prepaid DHL packages  
319 sent to the hospital, or through the patient presenting themselves to the hospital.

#### 320 g. Data management

321 All data will be managed with respect to confidentiality and will not be used for any  
322 commercial purposes. A combination of software will be used throughout the patient timeline.  
323 For the initial consent of the patient, RedCap software application will be used. For further

324 questionnaires, the commercial and proprietary WEB-based platforms will be used for data  
325 collection with the objective of simulating real-world applications of the SPB system. As  
326 further discussed below, the data collected by the commercial platform will be transferred to  
327 the research team for statistical analysis and data storage. It will not be used commercial  
328 development, and all copies held by the commercial partner will be erased upon termination  
329 of the research project.

330 To connect to the user interface web-based platform, the subject of the study will have to  
331 provide a valid e-mail and password. The later information collected will serve as  
332 identification to access the user interface WEB-based platform and for user id and password  
333 recovery. The login information will be stored on a separate secured database and serve only  
334 as login information control. The subject will be provided with a unique anonymized “*patient*  
335 *identification number*” by the clinical research coordinator. The research data collected by the  
336 user interface WEB-based platform and the medication dispensing device including the  
337 answers from the various questionnaires, the time and dosage of medication update and its  
338 corresponding adherence calculation will be associated to the “*patient identification number*”.  
339 No other information allowing to identify the subject will be collected and stored into the  
340 database (name, address, phone number, ect.). Only the clinical research coordinator will be  
341 knowledgeable of the association of the “*patient identification number*” to the subject *per se*.

342 The data will be automatically streamlined into a secured web-based electronic data collection  
343 system, without any intervention by the patient. The data collected will be anonymized and  
344 stored into dataset located on a Canadian-based highly secured server. At the end of the study,  
345 all anonymized data and database will be completely erased from AppMed’s systems and  
346 storage media. This destruction will be carried out securely to ensure that the data cannot be  
347 retrieved or used in the future. The user interface used to support the data collection into the  
348 database will consist of either *Thess* software (Thess, France) or *P-dose* software (AppMed  
349 inc., Quebec, Canada) depending on availability of the latter solution at the time of data  
350 collection. If the data recorded into the database is to be transferred from one database to  
351 another resulting from a change of user interface software, the procedure will be performed  
352 securely to mitigate any risks of data leaks and former database will be disposed according to  
353 the procedures described above. No private information or metadata, such as geolocation,  
354 will be extracted. All copies held by the commercial partner within their database will be erased  
355 upon termination of the research. No formal trial conduct auditing process will be performed.

356 Following the end of the trial, the research team will keep a copy of the data that will be  
357 retained for a period of 7 years. Paper copies (consent form) of patient information will be  
358 stored in a locked file cabinet in a locked office in the Department of Anesthesiology. Data  
359 will be assigned a unique study code which will be linked to the subject’s identities. The link  
360 will be kept separately from the data so that no patient can be identified in the event of loss or  
361 theft.

362 Every person involved in this study will receive appropriate training and abide by  
363 confidentiality guidelines to protect the subject's privacy. All Health Information Protection  
364 Act rules and regulations will be strictly followed. The identification data will not be re-used  
365 or disclosed to a third party except as required by law, for authorized oversight of the research,  
366 or as permitted by an authorization signed by the research subject. The study has a low level  
367 of risk. The PI or designated personnel will regularly review all data, such as study  
368 completeness, enrollment, protocol deviations, dropouts, and adverse events, on a weekly or  
369 bi-weekly basis. Therefore, a data monitoring committee (DMC) will not be needed.

#### 370 **4. Data Analyses**

##### 371 *Sample Size*

372 Based on available data in the literature concerning adherence to medication with the use of a  
373 SPB, we assume that we will estimate an adoption rate of 80%. This estimation is conservative  
374 when compared to Toscos et al. (11), who reported an adherence rate of 90% for patients using  
375 SPB for anticoagulant adherence. A precision of  $\pm 10\%$  will permit us to conclude that the  
376 observed adherence may be different than previously recorded ones. At a confidence level of  
377 95%, 62 patients are required to have the precision needed on our adherence point estimate.  
378 To account for a potential dropout ratio of 10.0%, the number was inflated to 69 patients.

##### 379 *Main Analyses*

380 The descriptive analysis of the primary outcome and secondary categorical outcome will be  
381 presented as a frequency (%), which will be reported with the boundaries of the 95%  
382 confidence interval (CI). Continuous data will be presented using mean and standard deviation,  
383 or median and interquartile range if the distribution is skewed or not normal. According to the  
384 nature of the analyzed endpoints, 95% CI will be presented.

385 More specifically, we will conduct a descriptive analysis of the consumptions gathered per  
386 hour, per patient, the total opioid consumption for each patient (converted in daily oral  
387 morphine equivalents), the percentage of captured consumptions, assessed by the number of  
388 opioid capsules consumption properly tracked by the SPB, divided by the total number of  
389 capsules missing at the end of the protocol, the number of losses of follow up, the rate of  
390 response to the questionnaires on the WEB-based platform and the number of patients that  
391 needed to be reached by telephone, patient satisfaction with the product along with the costs  
392 incurred from carrying out the project. Missing data will be replaced by the maximum value  
393 observed (worst-case scenario).

394 When comparing with the historical cohort of POCAS, risk differences or mean differences  
395 with 95% confidence intervals will be reported for all outcomes, including the costs incurred  
396 by carrying out the project. The alpha value will be set at 0.05 to establish statistical

397 significance. All data will be analyzed by the intention to treat principle. All statistical analysis  
398 will be performed using SAS, SPSS software or python/R programming language via VS Code  
399 or Jupyter notebook software.

400 We will also report metrics such as the SPB adoption rate and user satisfaction with the system  
401 stratified by patient demographics. For example, we will stratify results by age by splitting  
402 them at the median and comparing any differences. We will also conduct subgroup analyses  
403 on these outcomes by comparing opioid-naïve participants and opioid users along with the  
404 presence of any mental health condition reported in the initial comorbidity assessment. We  
405 will demonstrate the data collected on opioid consumption by the patients during the 90-day  
406 study period for each hour to provide an overview of the granularity of data.

407 For our exploratory objective, we will conduct a predictive analysis for the occurrence of POC,  
408 by using the trajectory of opioid consumption and the granular data of medication intake  
409 acquired throughout the 90-day period. We will explore machine learning and deep learning  
410 algorithms to predict POC at 90-days, while using the data collected as an input (demographics,  
411 time series of opioid consumption, etc.). The performance of the model will be assessed via  
412 *receiving operator characteristics* (ROC) curve and area under ROC (AUROC), precision,  
413 recall. Depending on the number of POC observed, we may amplify the true positive data by  
414 duplication. We will explore how newly crafted features (i.e. consumption of opioids at night)  
415 impacts the performance of the model. Finally, we will explore how the model performs at  
416 predicting POC, depending on the timing of prediction, throughout the 90-day period.

#### 417 *Loss of follow-up*

418 The number of patients lost to follow-up is expected to be limited due to the lending of the  
419 SPB, which will have to be retrieved. Patients who pass away before completion of treatment  
420 will be considered as lost to follow-up. In cases where they cannot be reached, it will be  
421 assumed that they have deviated from the proper use of the SPB, and they will be counted as  
422 non-adherent to the product. Subsequently, we will conduct several sensitivity analyses to  
423 investigate the implications of these lost-to-follow-up patients.

#### 424 *Sensitivity Analyses*

425 For our primary and secondary outcomes, we will use two models to explore the robustness of  
426 our findings and the impact of outcome measurement missingness due to the competing risk  
427 of death. We will fit models using the information gathered from proxies (spouse or family) or  
428 the medical chart of patients who have died by 3 months (potentially biased information) as  
429 well as one model with adherence amputated on those patients and one amputating no  
430 adherence on the same patients (best- and worst-case scenarios analyses).

431

## 432 5. Ethical Considerations

433 The study will adhere to the protocol, the Declaration of Helsinki, Good Clinical Practice  
434 (GCP), and relevant Canadian laws and regulations. This protocol has been approved by CER-  
435 CEMTL (CIUSSS de l'Est-de-l'Île-de-Montréal) Research Ethics Board (REB). Any  
436 amendments to the project will also undergo REB approval. Furthermore, the Thess Therapy  
437 Smart System will have undergone approval for patient use by Health Canada before the start  
438 of the trial.

439 Prior to starting the study, patients will be contacted by telephone at least 3 days before their  
440 surgery. We will describe the project and, if participation interest is confirmed, ask them to  
441 consent to data collection preoperatively and postoperatively through the Thess device for a 3-  
442 month period. In cases where patients are unable to provide an electronic signature via RedCap,  
443 we will obtain verbal consent during our first contact by telephone and finalize the consent  
444 process by obtaining written consent the day of the surgery. For patients we meet on the day  
445 of surgery, we will secure written consent before proceeding with preoperative interviews,  
446 whether conducted by phone or in person.

447 We will request a consent model from CIUSSS de l'Est-de-l'Île-de-Montréal's REB that  
448 incorporates Article 3.7A of the TCPS2 concerning modifications to the consent process and  
449 partial disclosure. Patients will be made familiar with the Thess Therapy Smart System device  
450 and will be informed of the primary objective of this study which is to evaluate the capabilities  
451 of the device in data collection. They will be instructed to use the device only for medication  
452 consumption to avoid erroneous inputs. We will inform patients that the study focuses on the  
453 use of SPBs for medication intake without disclosing the secondary objective, which is  
454 measuring persistent opioid consumption. We believe that disclosing the objective could lead  
455 to a conscious change in behavior related to medication consumption and introduce bias. This  
456 partial disclosure may improve data accuracy regarding patients' opioid use, and secondary  
457 comparison with the historical cohort of POCAS trial. We will ensure that patients do not feel  
458 inhibited or judged about their potential opioid consumption, as it will be presented as a  
459 potentially normal behavior three months after surgery. Following completion of the study,  
460 after having completed all questionnaires, participating patients will be contacted by phone  
461 call to explain the secondary purpose of the study and the rationale behind the initial partial  
462 disclosure as described above. Following this summary, patients will be asked if they still  
463 consent to participate in the study knowing its full scope and if not, the data will be destroyed.  
464 We believe that fully disclosing the secondary objective upfront would impede our ability to  
465 accurately measure the secondary outcome.

466 Patient information collected either through chart review, through surveys on the web platform  
467 or automatically through the SPB device will be securely stored for a period of 7 years on a  
468 protected server within the research lab of Maisonneuve-Rosemont hospital, maintaining strict

469 confidentiality. This data will not be used in ancillary studies. Each patient will receive a  
470 unique trial identification number to safeguard anonymity, which will correspond to allocation  
471 data in secure electronic records. Research personnel will be instructed to segregate any patient  
472 data containing personal identifiers, storing them under their respective ID numbers. The trial  
473 master file will be securely maintained at the study site throughout the research period. No data  
474 allowing the identification of study participants will be revealed in any publications, ensuring  
475 their anonymity. Any individual medical data obtained during the study will be treated as  
476 confidential and not disclosed to third parties except under specific circumstances:

477 - Medical information might be shared with the subject's personal physician or other  
478 relevant medical professionals overseeing the subject's care with the patient's consent.

479 - The data resulting from the study will be accessible for inspection upon request by  
480 participating physicians, Research Ethics Boards (REBs), and regulatory authorities.

481 Patients experiencing significant pain will have the option for a telephone follow-up aimed at  
482 assisting them in accessing suitable care. If the principal investigator observes that pain  
483 remains uncontrolled despite necessary follow-up, the patient will be offered a consultation at  
484 the HMR Pain Clinic. Since patients will be queried about opioid-related issues, our aim is to  
485 motivate them to seek assistance when necessary and to provide referrals to appropriate  
486 resources in cases of psychological distress associated with opioid use. Furthermore,  
487 interventions may be warranted in cases where significantly high intake of opioid is reported  
488 by a patient's Thess device.

489

## 490 **6. Feasibility**

### 491 *Financial aspects*

492 The SPBs will be provided by the distributor at no cost. However, as the SPBs only function  
493 using encapsulated medication for the moment, expenses associated with encapsulating opioid  
494 pills must be considered. As most patients typically require opioid medication for only a few  
495 days post-surgery (24), the quantity of pills requiring encapsulation will remain economically  
496 feasible. Despite the level of automation involved in the data collection, the most important  
497 expenses will be linked to the human resources required. These expenses which will be paid  
498 from active grants accounts.

## 499 **7. Strengths and Limitations**

500 This study will help evaluate smart pill bottles as data collection tools through an accurate  
501 comparison in time and context with the classical method reliant on human resources. Positive  
502 findings may introduce a revolutionary data acquisition method that would open the door to

503 large-scale projects involving large cohorts of patients, while benefiting from a reduction in  
504 associated costs. A significant amount of resources is dedicated to clinical research, but few  
505 studies seek to improve the research processes themselves, and to objectively document the  
506 improvement of these processes. In this sense, this innovative project has the potential to  
507 modernize research data collection strategies, demonstrating an advantage in terms of both  
508 quality and cost.

509 Our study may be limited due to the nature of the technology that records medication intake  
510 through sensors that monitor the number of times the pill box was opened rather than the true  
511 amount of consumed medication. This design characteristic may lead to inaccuracies in the  
512 data reported by the devices. Additionally, the device's dependence on encapsulated  
513 medication could result in escalated expenses due to the encapsulation procedure. While this  
514 cost is specific to the study's focus on opioids and the device's operational constraints, we will  
515 need to discuss the potential cost advantages that would arise from addressing this challenge.  
516 Furthermore, the nature of the treatment regimen of our cohort (medication to take as needed)  
517 may make an adherence analysis more challenging than with a scheduled treatment, as patients  
518 may stop taking the medication without indicating the reason through the questionnaires.

519 Moreover, the study's duration and the restricted frequency of patient assessments in the  
520 POCAS study might underestimate the potential cost savings generated by implementing  
521 Smart Pill Bottles (SPBs). In research requiring multiple contacts with participants, the cost  
522 differential between human resource-based data collection and SPB automated monitoring  
523 could be substantially more pronounced.

## 524 **8. Declaration of interests**

525 Dr PLL declares ownership interest in private companies unrelated to this work (Divocco  
526 Medical and Divocco AI). Other authors declare no competing interests.

## 527 **9. Access to data**

528 Only the PI, the co-investigators and the research staff will have access to all the data during  
529 the study and study analysis.

## 530 **10. Dissemination policy**

531 We plan to publish the results of this trial in a high-impact factor journal in the field of  
532 anesthesia, or medical technology.

533 Patients or the public were not involved in the design, or conduct, or reporting, or dissemination  
534 plans of our research. Full protocol as well as supplementary data from this study could be  
535 made available upon request to the PI. To be eligible for authorship, contributors must have

536 significantly participated in the creation, development, or enrollment of participants or  
537 statistical analysis of the study.

538 We plan on granting public access to the full protocol through publication. Participant-level  
539 dataset and statistical code can be made available upon reasonable request to the corresponding  
540 author.

## 541 **11. Author Contributions**

542 Conceptualization – ND, JB, JZ, LM and PLL; Investigation – ND, JB and PLL; Methodology  
543 – ND, JB, JZ, LM, FMC, OV and PLL; Supervision – PLL; Writing (Original Draft  
544 Preparation) – ND and JB; Writing (Review & Editing) – ND, LM and PLL.

## 545 **12. Acknowledgements**

546 Thanks to all the research team at LIAM (Laboratory of innovative anesthesia in Montreal) for  
547 its help in the research organization.

548

549

550

551

552

553

554

555

556

557

558

559

560

561



## 562 **References**

- 563 1. Beaney, A. (2024, January 5). Most significant clinical trials of 2023. Clinical Trials Arena.  
564 <https://www.clinicaltrialsarena.com/features/most-impactful-clinical-trials-2023-round-up/?cf-view>
- 565 2. Akl, E. A., Briel, M., You, J. J., Sun, X., Johnston, B. C., Busse, J. W., Mulla, S., Lamontagne, F., Bassler, D.,  
566 Vera, C., Alshurafa, M., Katsios, C. M., Zhou, Q., Cukierman-Yaffe, T., Gangji, A., Mills, E. J., Walter, S. D., Cook,  
567 D. J., Schünemann, H. J., Altman, D. G., ... Guyatt, G. H. (2012). Potential impact on estimated treatment effects of  
568 information lost to follow-up in randomised controlled trials (LOST-IT): systematic review. *BMJ (Clinical research*  
569 *ed.)*, 344, e2809. <https://doi.org/10.1136/bmj.e2809>
- 570 3. Setia MS. Methodology Series Module 1: Cohort Studies. *Indian J Dermatol*. 2016 Jan-Feb;61(1):21-5. doi:  
571 10.4103/0019-5154.174011. PMID: 26955090; PMCID: PMC4763690.
- 572 4. Toledano MB, Smith RB, Brook JP, Douglass M, Elliott P. How to Establish and Follow up a Large Prospective  
573 Cohort Study in the 21st Century--Lessons from UK COSMOS. *PLoS One*. 2015 Jul 6;10(7):e0131521. doi:  
574 10.1371/journal.pone.0131521. PMID: 26147611; PMCID: PMC4492973.
- 575 5. Barrera-Valencia C, Perea-Flórez EX. Comparison of Costs in Teledermatology Using PC and Camera Versus  
576 Smartphone. *Telemed J E Health*. 2024 Apr 26. doi: 10.1089/tmj.2023.0369. Epub ahead of print. PMID: 38669106.
- 577 6. Pavlović I, Miklavcic D. Web-based electronic data collection system to support electrochemotherapy clinical  
578 trial. *IEEE Trans Inf Technol Biomed*. 2007 Mar;11(2):222-30. doi: 10.1109/titb.2006.879581. PMID: 17390992.
- 579 7. Zijp TR, Touw DJ, van Boven JFM. User Acceptability and Technical Robustness Evaluation of a Novel Smart  
580 Pill Bottle Prototype Designed to Support Medication Adherence. *Patient Prefer Adherence*. 2020 Mar 20;14:625-  
581 634. doi: 10.2147/PPA.S240443. PMID: 32256053; PMCID: PMC7093103.
- 582 8. Gargioni, L., Fogli, D., & Baroni, P. (2024). A Systematic Review on Pill and Medication Dispensers from a  
583 Human-Centered Perspective. *Journal of healthcare informatics research*, 8(2), 244–285.  
584 <https://doi.org/10.1007/s41666-024-00161-w>
- 585 9. Schwed A, Fallab CL, Burnier M, Waeber B, Kappenberger L, Burnand B, Darioli R. Electronic monitoring of  
586 compliance to lipid-lowering therapy in clinical practice. *J Clin Pharmacol*. 1999 Apr;39(4):402-9. doi:  
587 10.1177/00912709922007976. PMID: 10197299.
- 588 10. Ellsworth GB, Burke LA, Wells MT, Mishra S, Caffrey M, Liddle D, Madhava M, O'Neal C, Anderson PL,  
589 Bushman L, Ellison L, Stein J, Gulick RM. Randomized Pilot Study of an Advanced Smart-Pill Bottle as an Adherence  
590 Intervention in Patients With HIV on Antiretroviral Treatment. *J Acquir Immune Defic Syndr*. 2021 Jan 1;86(1):73-  
591 80. doi: 10.1097/QAI.0000000000002519. PMID: 33306564; PMCID: PMC7735215.
- 592 11. Patel, T., Ivo, J., Pitre, T., Faisal, S., Antunes, K., & Oda, K. (2022). An In-Home Medication Dispensing System  
593 to Support Medication Adherence for Patients With Chronic Conditions in the Community Setting: Prospective  
594 Observational Pilot Study. *JMIR formative research*, 6(5), e34906. <https://doi.org/10.2196/34906>
- 595 12. Izzah, Z., Zijp, T. R., Åberg, C., Touw, D. J., & van Boven, J. F. M. (2022). Electronic Smart Blister Packages to  
596 Monitor and Support Medication Adherence: A Usability Study. *Patient preference and adherence*, 16, 2543–2558.  
597 <https://doi.org/10.2147/PPA.S374685>

- 598 13. Mauro, J., Mathews, K. B., & Sredzinski, E. S. (2019). Effect of a Smart Pill Bottle and Pharmacist Intervention  
599 on Medication Adherence in Patients with Multiple Myeloma New to Lenalidomide Therapy. *Journal of managed*  
600 *care & specialty pharmacy*, 25(11), 1244–1254. <https://doi.org/10.18553/jmcp.2019.25.11.1244>
- 601 14. Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. *Ann Acad Med Singap*. 1994  
602 Mar;23(2):129-38. PMID: 8080219.
- 603 15. Huo T, Guo Y, Shenkman E, Muller K. Assessing the reliability of the short form 12 (SF-12) health survey in  
604 adults with mental health conditions: a report from the wellness incentive and navigation (WIN) study. *Health Qual*  
605 *Life Outcomes*. 2018 Feb 13;16(1):34. doi: 10.1186/s12955-018-0858-2. PMID: 29439718; PMCID: PMC5811954.
- 606 16. Pagé MG, Kudrina I, Zomahoun HTV, Croteau J, Ziegler D, Ngangue P, Martin E, Fortier M, Boisvert EE,  
607 Beaulieu P, Charbonneau C, Cogan J, Daoust R, Martel MO, Néron A, Richebé P, Clarke H. A Systematic Review of  
608 the Relative Frequency and Risk Factors for Prolonged Opioid Prescription Following Surgery and Trauma Among  
609 Adults. *Ann Surg*. 2020 May;271(5):845-854. doi: 10.1097/SLA.0000000000003403. PMID: 31188226.
- 610 17. Roffman, C. E., Buchanan, J., & Allison, G. T. (2016). Charlson Comorbidities Index. *Journal of*  
611 *physiotherapy*, 62(3), 171. <https://doi.org/10.1016/j.jphys.2016.05.008>
- 612 18. Löwe, B., Wahl, I., Rose, M., Spitzer, C., Glaesmer, H., Wingenfeld, K., Schneider, A., & Brähler, E. (2010). A  
613 4-item measure of depression and anxiety: validation and standardization of the Patient Health Questionnaire-4 (PHQ-  
614 4) in the general population. *Journal of affective disorders*, 122(1-2), 86–95. <https://doi.org/10.1016/j.jad.2009.06.019>
- 615 19. Walton, D. M., Mehta, S., Seo, W., & MacDermid, J. C. (2020). Creation and validation of the 4-item BriefPCS-  
616 chronic through methodological triangulation. *Health and quality of life outcomes*, 18(1), 124.  
617 <https://doi.org/10.1186/s12955-020-01346-8>
- 618 20. Harris, P. A., Delacqua, G., Taylor, R., Pearson, S., Fernandez, M., & Duda, S. N. (2021). The REDCap Mobile  
619 Application: a data collection platform for research in regions or situations with internet scarcity. *JAMIA open*, 4(3),  
620 oaab078. <https://doi.org/10.1093/jamiaopen/oaab078>
- 621 21. Nafziger AN, Barkin RL. Opioid Therapy in Acute and Chronic Pain. *J Clin Pharmacol*. 2018 Sep;58(9):1111-  
622 1122. doi: 10.1002/jcph.1276. Epub 2018 Jul 9. PMID: 29985526.
- 623 22. Schug SA, Lavand'homme P, Barke A, Korwisi B, Rief W, Treede RD; IASP Taskforce for the Classification  
624 of Chronic Pain. The IASP classification of chronic pain for ICD-11: chronic postsurgical or posttraumatic pain. *Pain*.  
625 2019 Jan;160(1):45-52. doi: 10.1097/j.pain.0000000000001413. PMID: 30586070.
- 626 23. Richebé P, Capdevila X, Rivat C. Persistent Postsurgical Pain: Pathophysiology and Preventative Pharmacologic  
627 Considerations. *Anesthesiology*. 2018 Sep;129(3):590-607. doi: 10.1097/ALN.0000000000002238. PMID:  
628 29738328.
- 629 24. Schirle, L., Stone, A.L., Morris, M.C. et al. Leftover opioids following adult surgical procedures: a systematic  
630 review and meta-analysis. *Syst Rev* 9, 139 (2020). <https://doi.org/10.1186/s13643-020-01393-8>

631

632

633

## 634 Appendix 1 Trial Registration Dataset


<b>Data category</b>	<b>Information</b>
Primary Registry and Trial Identifying Number	ClinicalTrials.gov NCT06522698
Date of Registration in Primary registry	July 25 <sup>th</sup> , 2024
Secondary Identifying Numbers	Unique Protocol ID: 2025-3801
Source(s) of Monetary or Material Support	CR-HMR and the Department of Anesthesiology and Pain Medicine and Paperplane Therapeutics
Primary Sponsor	Centre intégré universitaire de santé et des services sociaux (CIUSSS) de l'est de l'île-de-Montréal (CEMTL)
Secondary Sponsor(s)	None
Contact for Public Queries	Pascal Laferrière-Langlois (pascal.laferriere-langlois@umontreal.ca)
Contact for Scientific Queries	Pascal Laferrière-Langlois (pascal.laferriere-langlois@umontreal.ca)
Public Title	Using smart pill bottles to optimize data collection in clinical trials: a study protocol
Scientific Title	Optimizing Research Data Acquisition with Smart Pill Bottles (SPBs), the ORDAS Trial: A Feasibility and Implementation Study Protocol
Countries of Recruitment	Canada
Health Condition(s) or Problem(s) Studied	Limitations related to the use of human resources in clinical trials
Intervention(s) Key Inclusion and Exclusion Criteria	Use of Smart pill bottles for postoperative opioid consumption Inclusion criteria: Full consent, aged 18 years or older, undergoing major abdominal surgery by laparotomy Exclusion criteria: Patients enrolled in the historical cohort (POCAS study) or currently participating in another study, patients undergoing additional surgery within 90 days post-hospital discharge, patients who do not understand French or English.
Study Type	Single arm, feasibility study
Date of First Enrollment	November 31 <sup>st</sup> , 2024 (Anticipated)
Sample Size	69 participants (Anticipated)

Recruitment Status	Not yet recruiting
Primary Outcome(s)	Percentage of patients successfully adopting the SPB
Key Secondary Outcomes	Automation of data collection Granularity of the data Total dose of opioid consumed Percentage of consumptions captured by the SPB Percentage of questionnaires properly filled Patient satisfaction with the use of the SPB Percentage of patients who respected the initial prescription of opioid made by the physician upon hospital discharge Total cost incurred per patient from carrying out the project Persistent opioid consumption (POC) 90 days after surgery The presence of CPSP in the 7 days prior to the interrogation The change in the reported quality of life
Ethics Review	Approved by the regional ethics committee (Comité d'éthique en recherche - CIUSSS de l'Est de l'Île de Montréal) on July 30 <sup>th</sup> , 2024
Completion date	November 30 <sup>th</sup> , 2026 (Anticipated)
Summary Results	None
IPD sharing statement	Individual clinical trial participant-level data will be made available upon request to the corresponding author, while maintaining strict patient confidentiality.

635

636

# Figure 1 SPIRIT Schedule of enrolment, interventions and assessments



- 1 Eligibility screen, informed consent, assessment of baseline characteristics, questionnaires: BPI, CCI, PHQ-4, PCS-4, SF-12
- 2 Training with the SPB prior to hospital discharge
- 3 Use of the SPB by the patient at home for pain medication consumption
- 4 Potential termination of the use of the SPB (48h + 5-day safety period) and retrieval of the SPB
- 5 End of the study period, questionnaires: BPI, PHQ-4, PCS-4, self-reported opioid consumption questionnaire, OCC Checklist, SF-12 and patient satisfaction questionnaire